255 related articles for article (PubMed ID: 24735367)
21. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway.
Sagawa M; Nakazato T; Uchida H; Ikeda Y; Kizaki M
Cancer Sci; 2008 Sep; 99(9):1820-6. PubMed ID: 18544087
[TBL] [Abstract][Full Text] [Related]
22. HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: therapeutic considerations.
Kim HL; Cassone M; Otvos L; Vogiatzi P
Cancer Biol Ther; 2008 Jan; 7(1):10-4. PubMed ID: 18347418
[TBL] [Abstract][Full Text] [Related]
23. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
25. The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways co-operate to mediate the activation of the hsp90beta gene by interleukin-6 but have opposite effects on its inducibility by heat shock.
Stephanou A; Isenberg DA; Akira S; Kishimoto T; Latchman DS
Biochem J; 1998 Feb; 330 ( Pt 1)(Pt 1):189-95. PubMed ID: 9461509
[TBL] [Abstract][Full Text] [Related]
26. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.
De Vos J; Jourdan M; Tarte K; Jasmin C; Klein B
Br J Haematol; 2000 Jun; 109(4):823-8. PubMed ID: 10929036
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC
Br J Haematol; 2011 Feb; 152(4):367-79. PubMed ID: 21219297
[TBL] [Abstract][Full Text] [Related]
28. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
29. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.
Allegra A; Sant'antonio E; Penna G; Alonci A; D'Angelo A; Russo S; Cannavò A; Gerace D; Musolino C
Eur J Haematol; 2011 Feb; 86(2):93-110. PubMed ID: 21114539
[TBL] [Abstract][Full Text] [Related]
30. Heat shock proteins in multiple myeloma.
Zhang L; Fok JH; Davies FE
Oncotarget; 2014 Mar; 5(5):1132-48. PubMed ID: 24675290
[TBL] [Abstract][Full Text] [Related]
31. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.
Stühmer T; Chatterjee M; Grella E; Seggewiss R; Langer C; Müller S; Schoepfer J; Garcia-Echeverria C; Quadt C; Jensen MR; Einsele H; Bargou RC
Br J Haematol; 2009 Nov; 147(3):319-27. PubMed ID: 19686236
[TBL] [Abstract][Full Text] [Related]
32. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3.
Piazza F; Manni S; Semenzato G
Leuk Res; 2013 Feb; 37(2):221-7. PubMed ID: 23174190
[TBL] [Abstract][Full Text] [Related]
33. The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.
Canovas Nunes S; Manzoni M; Pizzi M; Mandato E; Carrino M; Quotti Tubi L; Zambello R; Adami F; Visentin A; Barilà G; Trentin L; Manni S; Neri A; Semenzato G; Piazza F
Blood Cancer J; 2018 Feb; 8(2):20. PubMed ID: 29440639
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
Workman P
Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
[TBL] [Abstract][Full Text] [Related]
35. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
37. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.
Isomäki P; Junttila I; Vidqvist KL; Korpela M; Silvennoinen O
Rheumatology (Oxford); 2015 Jun; 54(6):1103-13. PubMed ID: 25406356
[TBL] [Abstract][Full Text] [Related]
38. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
39. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.
Meads MB; Fang B; Mathews L; Gemmer J; Nong L; Rosado-Lopez I; Nguyen T; Ring JE; Matsui W; MacLeod AR; Pachter JA; Hazlehurst LA; Koomen JM; Shain KH
Oncogene; 2016 May; 35(21):2723-34. PubMed ID: 26387544
[TBL] [Abstract][Full Text] [Related]
40. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
